EA202092335A1 - Композиции на основе эренумаба и пути их применения - Google Patents

Композиции на основе эренумаба и пути их применения

Info

Publication number
EA202092335A1
EA202092335A1 EA202092335A EA202092335A EA202092335A1 EA 202092335 A1 EA202092335 A1 EA 202092335A1 EA 202092335 A EA202092335 A EA 202092335A EA 202092335 A EA202092335 A EA 202092335A EA 202092335 A1 EA202092335 A1 EA 202092335A1
Authority
EA
Eurasian Patent Office
Prior art keywords
erenumab
variants
ways
application
compositions based
Prior art date
Application number
EA202092335A
Other languages
English (en)
Inventor
Кеннет Лоусон
Ноэль Ридер
Суминда Хапуараччи
Хосе Грегорио Рамирес
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA202092335A1 publication Critical patent/EA202092335A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/46—Flow patterns using more than one column
    • G01N30/461—Flow patterns using more than one column with serial coupling of separation columns
    • G01N30/463—Flow patterns using more than one column with serial coupling of separation columns for multidimensional chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к композициям, содержащим эренумаб и один или несколько вариантов эренумаба, включая изомеризованные варианты, дезамидированные варианты, кислые варианты и HMW-разновидности. Также описаны фармацевтические составы, содержащие композиции на основе эренумаба, и способы применения и определения характеристик композиций.
EA202092335A 2018-04-02 2019-04-01 Композиции на основе эренумаба и пути их применения EA202092335A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862651651P 2018-04-02 2018-04-02
PCT/US2019/025223 WO2019195185A1 (en) 2018-04-02 2019-04-01 Erenumab compositions and uses thereof

Publications (1)

Publication Number Publication Date
EA202092335A1 true EA202092335A1 (ru) 2021-01-22

Family

ID=66248665

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092335A EA202092335A1 (ru) 2018-04-02 2019-04-01 Композиции на основе эренумаба и пути их применения

Country Status (19)

Country Link
US (2) US11407838B2 (ru)
EP (1) EP3774881A1 (ru)
JP (2) JP2021519790A (ru)
KR (1) KR20200139720A (ru)
CN (1) CN111954678A (ru)
AR (1) AR114722A1 (ru)
AU (1) AU2019246983A1 (ru)
BR (1) BR112020019882A2 (ru)
CA (1) CA3095899A1 (ru)
CL (2) CL2020002519A1 (ru)
EA (1) EA202092335A1 (ru)
IL (1) IL277663A (ru)
MA (1) MA52202A (ru)
MX (1) MX2020010320A (ru)
PH (1) PH12020551618A1 (ru)
SA (1) SA520420261B1 (ru)
SG (1) SG11202009629YA (ru)
TW (1) TWI847980B (ru)
WO (1) WO2019195185A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CN118613503A (zh) * 2021-12-22 2024-09-06 中外制药株式会社 生物学活性降低的抗体变体

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1993019180A1 (en) 1992-03-17 1993-09-30 Ciba-Geigy Ag Genetically engineered antibodies
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
JP2002517406A (ja) 1998-06-01 2002-06-18 ジェネンテック・インコーポレーテッド イオン交換クロマトグラフィーの使用による、凝集体からのタンパク質モノマーの分離
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
JP4603261B2 (ja) 2001-09-27 2010-12-22 メルク・シャープ・エンド・ドーム・コーポレイション ヒト化カルシトニン遺伝子関連ペプチド受容体をコードする単離ｄｎａ分子、関連する非ヒトトランスジェニック動物及びアッセイ方法
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
RS52750B (sr) 2002-08-12 2013-08-30 Birkir Sveinsson Upotreba cgrp antagonista za lečenje psorijaze
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
RU2007118954A (ru) 2004-10-22 2008-11-27 Эмджен Инк. (Us) Способ рефолдинга рекомбинантных антител
AU2005310305A1 (en) 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
SI1838733T1 (sl) 2004-12-21 2011-12-30 Medimmune Ltd Protitelesa usmerjena na angiopoietin-2 in njih uporaba
US9072777B2 (en) 2005-06-16 2015-07-07 Takayuki Shindo Method for screening substance having proangiogenic effect
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
RS20080200A (en) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
RU2009107277A (ru) 2006-08-03 2010-09-10 Астразенека Аб (Se) АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
PL2265288T3 (pl) 2008-03-04 2017-01-31 Labrys Biologics Inc Sposoby leczenia bólu zapalnego
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
BRPI0921947A2 (pt) * 2008-11-20 2018-10-16 Genentech, Inc. formulações de proteína terapêutica
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
TW201039854A (en) * 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
BRPI1010119A2 (pt) * 2009-07-24 2016-03-15 Hoffmann La Roche "método de produção de composição de anticorpo e uso de cromatografia de troca de íons analítica"
WO2011024113A1 (en) 2009-08-28 2011-03-03 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
SG181771A1 (en) 2009-12-18 2012-07-30 Novartis Ag Wash solution and method for affinity chromatography
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
BR112013029959A8 (pt) 2011-05-20 2021-09-08 Alderbio Holdings Llc Anticorpos anti-cgrp e anti-cgrpr e seu uso para prevenir ou inibir fotofobia ou aversão à luz, composição farmacêutica compreendendo os referidos anticorpos, bem como sequência de ácido nucleico e célula recombinante
US9783570B2 (en) 2011-07-01 2017-10-10 Hoffmann-La Roche Inc. Method for separation of monomeric polypeptides from aggregated polypeptides
CA2857194A1 (en) * 2011-12-07 2013-06-13 Thomas M. Dillon Igg2 disulfide isoform separation
DK2791176T3 (en) * 2011-12-15 2018-10-15 Prestige Biopharma Pte Ltd PROCEDURE FOR CLEANING ANTIBODIES
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EA032830B1 (ru) 2013-03-15 2019-07-31 Эмджен Инк. Антитела к pac1 человека и их применение для лечения головной боли
KR102251127B1 (ko) * 2013-07-12 2021-05-11 제넨테크, 인크. 이온 교환 크로마토그래피 입력 최적화의 설명
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
LT3119431T (lt) 2014-03-21 2024-03-12 Teva Pharmaceuticals International Gmbh Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
JOP20200116A1 (ar) * 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp

Also Published As

Publication number Publication date
PH12020551618A1 (en) 2021-08-16
MA52202A (fr) 2021-02-17
CA3095899A1 (en) 2019-10-10
KR20200139720A (ko) 2020-12-14
EP3774881A1 (en) 2021-02-17
WO2019195185A1 (en) 2019-10-10
TWI847980B (zh) 2024-07-11
US20190300617A1 (en) 2019-10-03
JP2023103323A (ja) 2023-07-26
BR112020019882A2 (pt) 2021-01-05
US11407838B2 (en) 2022-08-09
CN111954678A (zh) 2020-11-17
AU2019246983A1 (en) 2020-10-29
AR114722A1 (es) 2020-10-07
SA520420261B1 (ar) 2024-05-23
CL2023000491A1 (es) 2023-10-13
US20220348673A1 (en) 2022-11-03
IL277663A (en) 2020-11-30
TW202003572A (zh) 2020-01-16
SG11202009629YA (en) 2020-10-29
CL2020002519A1 (es) 2021-04-05
JP2021519790A (ja) 2021-08-12
MX2020010320A (es) 2021-01-08

Similar Documents

Publication Publication Date Title
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA201890052A1 (ru) Регуляторы nrf2
EA202190726A1 (ru) Индольные ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение
EA202092586A1 (ru) Ингибиторы magl
EA202090296A1 (ru) Спироциклические соединения и способы их получения и применения
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
EA201991799A1 (ru) Диспергируемые в воде составы
EA201991798A1 (ru) Стабильные при хранении составы
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792262A1 (ru) Пироглутамат вортиоксетина
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA202090270A1 (ru) Новые замещенные производные ксантина
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
EA202090424A1 (ru) Бициклические ингибиторы гистондеацетилазы
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
EA202191403A1 (ru) Композиция с высокой концентрацией белка
EA202190217A1 (ru) Формы ивосидениба и фармацевтические композиции
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид